The post hoc analysis of patients only from the PIONEER 6 (evaluating oral semaglutide) and SUSTAIN 6 (evaluating sc semaglutide) studies found a 23.8% reduction in MACEs associated with semaglutide treatment (HR 0.76, 95% CI 0.620.92), especially in the prevention of nonfatal stroke (HR 0.65, 95% CI 0.430.97) [62]
Rosenstock, J., Nino, A., Soffer, J., Erskine, L., Acusta, A., Dole, J., Carr, M
We look for motivated and qualified applicants with a large network
DOI Ahnfelt-Rnne I, Nowak J, Olsen UB (2001)
[5] The work is early and mechanistic, but it points to a future where specific gut bacteria may be leveraged to support metabolic health, and it underscores how much of the GLP-1 story is written in the microbiome